This profile was last updated on //
Is this you? Claim your profile.
Wrong Michael Friedman?
Dr. Michael Friedman A.
28903 North Ave Paine
MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer. Its lead product candidate, AFRESA, is an ultra rapid-acting insu
Find other employees at this company (368)
(163 Total References)
Michael A. Friedman, ...
Michael A. Friedman, M.D.(1)(2)
Michael A. Friedman, M.D. has been one of our directors since December 2003.
In 2014, Dr. Friedman
completed a decade of service as the President and Chief Executive Officer of the City of Hope National Medical Center
Previously, from September 2001 until April 2003, Dr. Friedman held the position of Senior Vice President of Research and Development, Medical and Public Policy, for Pharmacia Corporation and, from July 1999 until September 2001, was a senior vice president of Searle, a subsidiary of Monsanto Company.
From 1995 until June 1999, Dr. Friedman served as Deputy Commissioner for Operations for the Food and Drug Administration, and was Acting Commissioner and Lead Deputy Commissioner from 1997 to 1998.
He joined the board of Celgene Corporation in February 2011 and the board of Smith & Nephew plc in April 2013.
Dr. Friedman received a bachelor of arts degree, magna cum laude, from Tulane University, New Orleans, Louisiana, and a doctorate in medicine from the University of Texas, Southwestern Medical School.
The Board believes Dr. Friedman’s business experience, including his experience as an executive officer at biopharmaceutical companies and a leading clinical and research center specializing in cancer and diabetes, and his service at the Food and Drug Administration, combined with his business acumen and judgment provide our Board with valuable scientific and operational expertise and leadership skills.
Michael Friedman (70) ...
Michael Friedman (70) Independent Non-executive Director
Michael was appointed Non-executive Director and elected by Shareholders at the Annual General Meeting on 11 April 2013.
He was appointed Chairman of the Ethics & Compliance Committee on 1 August 2014.
Michael was formerly Chief Executive Officer of City of Hope, the prestigious cancer research and treatment institution in California and is now Executive for Special Projects and Emeritus Cancer Center Director.
He has also served as director of the institution's comprehensive cancer centre and held the Irell & Manella Cancer Center Director's Distinguished Chair.
He was formerly senior vice president of research, medical and public policy for Pharmacia Corporation and has served as Deputy Commissioner and Acting Commissioner at the US ?Food and Drug Administration.
He has also served on a number of Boards in a Non-executive capacity, including RiteAid Corporation.
He is also Non-Executive Director of Celgene Corporation and Non-Executive Director of MannKind Corporation.
Board of Directors
Michael Friedman, M.D.
Michael Friedman, M.D. has been one of our directors since December 2003. more
DENTAL NEWS | Doctors Try Balloon Fix on Sinusitis | Dentist.net
"Clearly sinuplasty will not replace surgery for every patient," cautions Dr. Michael Friedman, an otolaryngologist and chief of head and neck surgery at Chicago's Rush University Medical Center, who heads the first study that will compare the treatments.
"But I think there's a huge number of people who could benefit from this," he
Instead, inflating the balloon aims to stretch that sinus opening back to its original size or a little bigger, letting air into the sinus to help antibiotics finally flush out infection and end the sinusitis cycle, explains Friedman
But to compare sinuplasty to standard treatments, Friedman
, who has no financial interest in Acclarent
, has begun a study that randomly assigns 80 sinusitis sufferers to surgery, sinuplasty or continued medication.
"This is the most exciting innovation ...
"This is the most exciting innovation for the treatment of sleep apnea since CPAP," said Michael Friedman, M.D., Professor of Otolaryngology and director of Chicago Sleep Center at Rush University Medical Center, Chicago IL and a study investigator.
"Essentially, the system keeps the tongue in an awake position while the patient sleeps," explains Dr. Michael Friedman